Top

Published in:

01-01-2015 | Original Article

Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer

Authors: Leah J. Novinger, Takamaru Ashikaga, David N. Krag

Published in: Cancer Immunology, Immunotherapy | Issue 1/2015

Abstract

The purpose of this study was to determine the clonal relationship between B cells within a breast cancer and the B cells in the tumor-draining lymph node (TDLN). We also determined the binding capacity of antibodies derived from these sources to autologous cancer and autologous noncancer breast tissue. Antibody clonality of B cells derived from tumor and lymph node was determined by analyzing heavy and light chain immunoglobulin sequences. The number of shared clonal groups observed between tumor and lymph node antibodies was significant for both heavy (p = 0.004) and light chain (p = 0.012) populations. Panning with phage-displayed single-chain variable fragment libraries derived from the tumor and lymph node B cells resulted in multiple antibodies that bound autologous tumor. Sequence analysis of enriched antibodies recovered after the third round of panning the tumor and TDLN libraries against autologous tumor lysates had a genetic relationship. These results indicate that B cells infiltrating a patient’s breast cancer and B cells present in the tumor-draining lymph node are clonally and functionally related.

Available only for authorised users

Spaner D, Bahlo A (2011) B lymphocytes in cancer immunology. In: Medin J, Fowler D (eds) Experimental and applied immunotherapy. Humana Press, New York, pp 37–57CrossRef

Nielsen JS, Nelson BH (2012) Tumor-infiltrating B cells and T cells: working together to promote patient survival. Oncoimmunology 1:1623–1625. doi:10.4161/onci.21650 PubMedCentralPubMedCrossRef

Coronella JA, Spier C, Welch M et al (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169:1829–1836PubMedCrossRef

Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63:3275–3280PubMed

Simsa P, Teillaud J-L, Stott DI et al (2005) Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. Pathol Oncol Res 11:92–97PubMedCrossRef

Wang Y, Ylera F, Boston M et al (2007) Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res Treat 104:129–144. doi:10.1007/s10549-006-9409-3 PubMedCrossRef

Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169:2701–2711PubMedCrossRef

Kotlan B, Simsa P, Teillaud J-L et al (2005) Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 175:2278–2285PubMedCrossRef

Pavoni E, Monteriù G, Santapaola D et al (2007) Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol 7:70. doi:10.1186/1472-6750-7-70 PubMedCentralPubMedCrossRef

10.

Rothe A, Klimka A, Tur MK et al (2004) Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines. Int J Mol Med 14:729–735PubMed

11.

Belimezi MM, Papanastassiou D, Merkouri E et al (2006) Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Cancer Immunol Immunother 55:1091–1099. doi:10.1007/s00262-005-0100-z PubMedCrossRef

12.

Ayat H, Burrone OR, Sadghizadeh M et al (2013) Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients. Biologicals 41(6):345–354. doi:10.1016/j.biologicals.2013.05.004 PubMedCrossRef

13.

Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933. doi:10.1016/S1470-2045(10)70207-2 PubMedCentralPubMedCrossRef

14.

De Cicco C, Chinol M, Paganelli G (1998) Intraoperative localization of the sentinel node in breast cancer: technical aspects of lymphoscintigraphic methods. Semin Surg Oncol 15:268–271PubMedCrossRef

15.

Setiadi AF, Ray NC, Kohrt HE et al (2010) Quantitative, architectural analysis of immune cell subsets in tumor-draining lymph nodes from breast cancer patients and healthy lymph nodes. PLoS ONE 5:e12420. doi:10.1371/journal.pone.0012420 PubMedCentralPubMedCrossRef

16.

Chang AY, Bhattacharya N, Mu J et al (2013) Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med 11:242. doi:10.1186/1479-5876-11-242 PubMedCentralPubMedCrossRef

17.

Wei S, Shreiner AB, Takeshita N et al (2008) Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res 68:5432–5438. doi:10.1158/0008-5472.CAN-07-6598 PubMedCentralPubMedCrossRef

18.

Li Q, Lao X, Pan Q et al (2011) Adoptive transfer of tumor reactive B cells confers host T cell immunity and tumor regression. Clin Cancer Res 17(15):4987–4995. doi:10.1158/1078-0432.CCR-11-0207 PubMedCentralPubMedCrossRef

19.

Zirakzadeh AA, Marits P, Sherif A, Winqvist O (2013) Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J Immunol 190:5847–5855. doi:10.4049/jimmunol.1203279 PubMedCrossRef

20.

Barbas CF III, Burton DR, Scott JK, Silverman GJ (2001) Phage display: a laboratory manual. Cold Spring Harbor Laboratory Press, New York

21.

Brochet X, Lefranc M-P, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36:W503–W508. doi:10.1093/nar/gkn316 PubMedCentralPubMedCrossRef

22.

Mehr R, Sternberg-Simon M, Michaeli M, Pickman Y (2012) Models and methods for analysis of lymphocyte repertoire generation, development, selection and evolution. Immunol Lett 148:11–22. doi:10.1016/j.imlet.2012.08.002 PubMedCrossRef

23.

Dixon WJ, Massey FJ (1983) Introduction to statistical analysis, 4th edn. McGraw-Hill Science, Engineering & Mathematics, New York

24.

Kao J, Salari K, Bocanegra M et al (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4:e6146. doi:10.1371/journal.pone.0006146 PubMedCentralPubMedCrossRef

25.

Shukla GS, Krag DN (2005) A sensitive and rapid chemiluminescence ELISA for filamentous bacteriophages. J Immunoass Immunochem 26:89–95. doi:10.1081/IAS-200051990 CrossRef

26.

Sun Y, Shukla GS, Kennedy GG et al (2009) Biopanning phage-display libraries on small tissue sections captured by laser capture microdissection. J Biotech Res 1:55–63PubMedCentralPubMed

27.

Chang B, Casali P (1994) The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today 15:367–373. doi:10.1016/0167-5699(94)90175-9 PubMedCrossRef

28.

Muramatsu M, Kinoshita K, Fagarasan S et al (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–563PubMedCrossRef

29.

Stavnezer J, Guikema JEJ, Schrader CE (2008) Mechanism and regulation of class switch recombination. Annu Rev Immunol 26:261–292. doi:10.1146/annurev.immunol.26.021607.090248 PubMedCentralPubMedCrossRef

30.

Thie H, Toleikis L, Li J et al (2011) Rise and fall of an anti-MUC1 specific antibody. PLoS ONE 6:e15921. doi:10.1371/journal.pone.0015921 PubMedCentralPubMedCrossRef

31.

Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 98:12659–12664. doi:10.1073/pnas.171460798 PubMedCentralPubMedCrossRef

32.

Kotlan B, Simsa P, Foldi J et al (2003) Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma. Hum Antibodies 12:113–121PubMed

33.

Lavinder JJ, Wine Y, Giesecke C et al (2014) Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci USA 111(6):2259–2264. doi:10.1073/pnas.1317793111 PubMedCentralPubMedCrossRef

Title: Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer
Authors: Leah J. Novinger
Takamaru Ashikaga
David N. Krag
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 1/2015
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-014-1612-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Evaluation of complement proteins as screening markers for colorectal cancer

Cancer stem cells: perspectives for therapeutic targeting

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

Overcoming the toxicity hurdles of genetically targeted T cells

Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer